# Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors

> **NCT05416359** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 70 (estimated)

## Conditions studied

- Advanced Malignant Tumor

## Interventions

- **DRUG:** TQB3915 tablets

## Key facts

- **NCT ID:** NCT05416359
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06
- **Primary completion:** 2023-06
- **Final completion:** 2024-06
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2022-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05416359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05416359, "Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05416359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*